Concepedia

Preclinical Efficacy Evaluations of XK-469: Dose Schedule, Route and Cross-Resistance Behavior in Tumor Bearing Mice

Lisa Polin, Kathryn White, Juiwanna Kushner, Jennifer Paluch, C.J. Simpson, Susan Pugh, Matthew Edelstein, Stuart Hazeldine, Joseph A. Fontana, Patricia LoRusso,

Investigational New Drugs · 2002 · 16 citations · 9 references

DOI

Concepts

References

9

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice.

Schabel Fm, Trader Mw, Laster Wr et al. · PubMed · 1980 · 433 citations

, , +15

Rodent tumor models in experimental cancer therapy

Albert J. van der Kogel · Radiotherapy and Oncology · 1988 · 167 citations

, , +12

Establishment of cross-resistance profiles for new agents.

Schabel Fm, Skipper He, Trader Mw et al. · PubMed · 1983 · 138 citations

, , +13

XK469, a selective topoisomerase IIβ poison

Hanlin Gao, Kuan‐Chun Huang, Edith F. Yamasaki et al. · Proceedings of the National Academy of Sciences · 1999 · 97 citations

, , +13

Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate

Thomas H. Corbett, Patricia LoRusso, Lisa Demchick et al. · Investigational New Drugs · 1998 · 63 citations

, , +8